Abstract
MicroRNAs (miRNAs) can impact viral infections by binding to sequences with partial complementarity on viral RNA transcripts, usually resulting in the repression of virus replication. In the present study, we identified a potential binding site for miR-130 in the 5' untranslated region (bps 155-162) of the porcine reproductive and respiratory syndrome virus (PRRSV) genome. We found that the delivery of multiple miR-130 family mimics, especially miR-130b, resulted in inhibition of PRRSV replication in vitro. miR-130 was effective in inhibiting the replication of multiple type 2 PRRSV strains, but not against vSHE, a classical type 1 strain. miR-130 over-expression did not induce IFN-α or TNF-α expression in either uninfected or PRRSV-infected porcine alveolar macrophages. Results from luciferase reporter assays indicated that miR-130 directly targeted the PRRSV 5' UTR. Intranasal inoculation of piglets with miR-130b exhibited antiviral activity in vivo and partially protected piglets from an otherwise lethal challenge with HP-PRRSV strain vJX143. Overall, these results demonstrate the importance of the miR-130 family in modulating PRRSV replication and also provide a scientific basis for using cellular miRNAs in anti-PRRSV therapies.
Introduction
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) remains a major economic burden for the global swine industry, causing reproductive failure and respiratory distress. Current control measures, such as vaccination, often fail due to the virus's high mutation rate and its ability to evade the host immune system. This study investigates the potential of host microRNAs (miRNAs) as a novel therapeutic approach to directly inhibit PRRSV replication.
Methods
The researchers employed a multi-faceted approach to evaluate the antiviral potential of miR-130b:
- Computational Prediction: The ViTa algorithm was used to identify potential miRNA binding sites within the PRRSV genome, pinpointing a conserved target for the miR-130 family in the 5′ UTR.
- In Vitro Validation: miRNA mimics were transfected into MARC-145 cells and Porcine Alveolar Macrophages (PAMs). Viral replication was assessed using qRT-PCR, Western blotting, and TCID₅₀ assays.
- Mechanism of Action: Luciferase reporter assays were conducted using plasmids containing the viral 5′ UTR to confirm direct binding between miR-130b and the viral RNA.
- In Vivo Efficacy: 4-week-old piglets received intranasal miR-130b mimics prior to challenge with the highly pathogenic PRRSV strain vJX143.
Results
Genomic Targeting and Conservation
The study identified a highly conserved 8-nucleotide target site for the miR-130 family within the 5′ UTR of Type 2 PRRSV strains. As shown in Figure 1, this site is notably absent in Type 1 (European) strains such as LV and SHE, which explains the genotype-specific efficacy observed in the study.
Potent In Vitro Inhibition
In PAMs, the natural target of PRRSV, miR-130b mimics reduced viral titers by approximately 1,000-fold compared to negative controls. This inhibition was dose-dependent and did not rely on the induction of interferon-α or TNF-α, indicating a direct RNA interference mechanism rather than general immune activation.
In Vivo Protection
The most significant finding was the protective effect in piglets. Intranasal delivery of miR-130b mimics resulted in a 75% survival rate following a lethal challenge with HP-PRRSV, whereas 100% of the control group died by day 10. Treated piglets also exhibited significantly lower viral loads in the blood (~1,000-fold reduction), reduced fever (averaging 1°C lower), and fewer lung lesions.
Discussion
This research highlights the 5′ UTR of the PRRSV genome as a critical vulnerability that can be exploited by host miRNAs. Unlike other miRNAs that act by modulating the immune response, miR-130b provides protection through direct interference with viral replication.
While promising, several challenges remain for clinical application. The potential for the virus to develop escape mutations suggests that a cocktail of miRNAs targeting multiple sites might be necessary. Additionally, scaling intranasal delivery for commercial swine production presents logistical and economic hurdles. Future research should also explore the broader cellular impact of overexpressing miR-130b and identify similar targets for Type 1 PRRSV strains.
Summary updated